Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare REX AI Equity Premium Income ETF (AIPI) vs ClearPoint Neuro Inc (CLPT) Price & Performance

REX AI Equity Premium Income ETF
ClearPoint Neuro Inc

Price performance

Price movement over the last 24 hours

Key statistics

REX AI Equity Premium Income ETF vs ClearPoint Neuro Inc — how do they compare? REX AI Equity Premium Income ETF trades at $36.06, while ClearPoint Neuro Inc trades at $17.14 (market cap $524.82M). The key difference: ClearPoint Neuro Inc is trading nearer its 52-week high, REX AI Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.

AIPICLPT
Sector
Income / Options OverlayHealth
52-Week High
$44.93$29.60
52-Week Low
$32.45$8.66
Market Cap
$524.82M
Enterprise Value
$552.81M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

REX AI Equity Premium Income ETF

AIPI trades at $37.10, up 1.87% with neutral technical signals. The ETF maintains a high weekly dividend distribution strategy, recently transitioning to weekly payouts. Technical analysis shows mixed signals with bullish moving averages but neutral oscillators, trading near key support at $37. Recent news highlights concerns about NAV erosion risk despite the attractive yield structure.

The outlook remains cautious due to structural limitations in the option-writing strategy that caps upside potential. While the ~34.8% yield appears attractive, sustainability depends heavily on AI market momentum. Investors face NAV erosion risk if technology sector performance falters, requiring careful monitoring of the fund's premium income strategy effectiveness.

ClearPoint Neuro Inc

ClearPoint Neuro (CLPT) trades at $18.00, down 3.85% with a bullish technical signal from moving averages. The company shows strong revenue growth with 25% organic device growth in Q1 2026 but continues to report significant losses, with a net income margin of -71.57%. Recent FDA clearance for the Velocity Alpha surgical drill and partnership expansion in South Korea highlight ongoing business development. Analyst sentiment remains strongly positive with 100% buy ratings, though the stock faces execution and regulatory risks.

The outlook remains speculative with high growth potential from gene therapy commercialization offset by persistent losses and cash burn. Investment opportunity lies in successful partner therapy commercialization, but risks include regulatory hurdles and the need for continued financing. The stock's valuation at 12.76x sales reflects growth expectations despite negative profitability metrics.

Returns comparison

Trailing returns across standard periods

About REX AI Equity Premium Income ETF

AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.

Read more on AIPI

About ClearPoint Neuro Inc

ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.

Read more on CLPT